Depression is a common and major psychiatric disorder characterized by symptoms involving sleep disturbance, loss of appetite, lack of interest, low self-worth, and even suicidal thoughts 1,2. The global prevalence of depression is 4.7% and the pooled annual incidence is 3.0% 3, indicating that ~350 million individuals are impacted by depression worldwide 4. Stress is a major trigger of depression, which manifests itself as the body’s response to a stimulus shown in the form of a mental and/or an emotional response 5.
The hypothalamic–pituitary–adrenal (HPA) axis is a neuroendocrine system involved in the production of the stress hormone cortisol. The steady state of the HPA axis is regulated by the glucocorticoid receptor (GR) through negative feedback in the hippocampus. However, stress-induced progressive HPA axis abnormalities can lead to high circulating levels of cortisol and high expression of GR, which not only triggers depression and anxiety-like changes in behavior 6 but also causes changes in the brain structure because of decreased neurotrophic activity. Serum-inducible and glucocorticoid-inducible kinase 1 (SGK1) is not only stimulated by glucocorticoids and serum but is also a downstream target of GR. SGK1 participates in the occurrence of depression through the glucocorticoid signaling pathway and maintains GR activity potentially without glucocorticoids by regulating GR phosphorylation levels 7. The GR/SGK1 signaling pathway is implicated in learning, memory, and neuroplasticity as well as the stress response and depression.
Neurite outgrowth has received the most attention as an indicator of neurodevelopment and neuroregeneration in vitro as the development of axonal and dendritic processes is a defining characteristic of neuronal cell morphology and a critical determinant of neuronal cell connectivity and function 8. The GR antagonist RU486 was shown to counteract the inhibitory effect of dexamethasone pretreatment on neurite extension from PC12 cells 9. Neurotrophic factors are vital for supporting neuronal survival and play a role in the process of regulating neuronal formation in neural networks. SGK1 acts downstream from corticosterone (CORT) to induce morphological changes in nerve cells 10. SGK1 regulates the neurotrophic support of hippocampal neurons by regulating brain-derived neurotrophic factor (BDNF) 11. In addition, the hippocampal shrinkage observed commonly in patients with depression has been linked to decreased neurotrophic support in association with high levels of cortisol 12,13. Also, clinic antidepressants fluoxetine has been shown to promote neurite outgrowth and regulate expression of the neurotrophic factors 14.
Leonurus cardiaca, a herbaceous perennial plant in the mint family, has a long history of use in traditional medicine in the treatment of a variety of diseases in China, Japan, Korea, and European countries. Leonurine, also called SCM-198 (4-guanidino-n-butyl syringate), is a chemically synthesized compound based on a bioactive alkaloid extracted from L. cardiaca15. Leonurine has recently been shown to be effective in the treatment of cardiovascular and nervous system disease 16. Jia et al.17 found that leonurine exerts antidepressant effects in a stress-induced depression animal model. This study also found that the ability of leonurine to ameliorate behavioral parameters was related to learning and memory, and that its mechanism mainly involved increasing monoamine neurotransmitters and inhibiting neuroinflammation. However, very few studies have examined the underlying molecular mechanisms. Therefore, in the present study, we hypothesized that leonurine could attenuate the negative effects of CORT on neurite outgrowth and neurotrophic molecules in PC12 cells by modulating the expression of GR and SGK1.
Materials and methods
Chemicals and reagents
Leonurine and CORT with purities of 98% were purchased from Sigma-Aldrich (St Louis, Missouri, USA). GR inhibitor RU486 and SGK1 inhibitor GSK650394 were also purchased from Sigma-Aldrich. Fluoxetine hydrochloride was acquired from Tianjin Tasly Pharmaceutical Co., Ltd (Tianjin, China). Leonurine was dissolved in DMSO (Sigma-Aldrich) and ethanol (50% v/v) and diluted in saline at a concentration of 20 μmol/ml.
Cell culture and drug treatments
PC12 cells originating from rat adrenal medulla were obtained from Procell Life Science & Technology Co., Ltd. (Wuhan, China). All cell culture reagents were obtained from Life Technologies (Grand Island, Nebraska, USA). Cells were maintained in Dulbecco’s modified Eagle’s medium (high glucose) supplemented with 5% fetal bovine serum (Gibco, Grand Island, Nebraska, USA) and 10% horse serum (Gibco), 100 U/ml penicillin, and 100 μg/ml streptomycin in a humidified CO2 (5%) incubator at 37°C.
PC12 cells are typically used to establish a depression model in vitro, which is accomplished by the administration of CORT 18. PC12 cells were treated with 300 μM CORT for 24 h. Cell viability decreased to ~50% at this concentration of CORT, which was therefore used in all subsequent experiments in vitro.
Part 1: To determine the effect of leonurine in a major depression model, the cells were divided into five groups: normal control, CORT+PBS, CORT+fluoxetine, and CORT+leonurine (10, 20, 40, 60, 80, and 100 μM). Analysis was carried out 24 h after the cells were seeded. Leonurine was applied 2 h before CORT treatment and the cells were cultured for another 24 h. Viability was then determined using an MTT assay.
Part 2: To research the molecular mechanism of leonurine in a major depression model, the cells were divided into seven groups: nontreated nornal (Normal), CORT+PBS (PBS), fluoxetine serum group (FLU), leonurine group (LEO), leonurine plus GR inhibitor group (LEO+RU), and leonurine+SGK inhibitor group (LEO+GSK). Drugs were diluted with neurobasal medium, and the culture medium was replaced with fresh neurobasal medium 3 h before any drug treatment.
Tetrazolium (MTT)-based colorimetric cell viability assay
Cell viability was assessed using an MTT [3-(4,5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide] assay. Cells were seeded in 96-well plates for 24 h and treated with drugs for 72 h before adding MTT. The cells were then incubated with MTT for another 3 h at 37°C. Thereafter, absorbance at 570 nm was measured in a microplate reader (Thermo Scientific, Fremont, California, USA).
Cell morphology, neurite outgrowth, and expression of immunofluorescent proteins
A set of tests are commercially available to evaluate cell morphology, neurite outgrowth, and expression of immunofluorescent proteins using a high content analysis (HCA) system (PerkinElmer, Boston, Massachusetts, USA). The method utilizes automated measurements in 96-well plates stained using the immunocytochemical procedure described below.
Following drug exposure, cells in transparent plates were fixed for 20 min in a fixative solution consisting of 4% paraformaldehyde and 10 μg/ml Hoechst 33342 in 1× PBS. Cell bodies were labeled using an anti-β-tubulin primary antibody (1 : 150; Proteintech, Chicago, Illinois, USA) and antibodies against GR, SGK1, BDNF, neurotrophic factor-3 (NT-3), and B-cell lymphoma-2 (BCL-2) (all 1 : 500; Abcam, Cambridge, UK), followed by an FITC-conjugated secondary antibody protected from light. The plate was washed three times with 100 μl of 1× PBS after each operation, retaining the buffer from the final wash. Plates were then loaded into the Operetta HCA device (PerkinElmer, Boston, Massachusetts, USA) for image capture and analysis.
The assay parameters cited in this method are associated with an optimized image analysis protocol for measuring neurite outgrowth in differentiated NS-1 cells. The acquired images were analyzed using the Harmony system (PerkinElmer, Boston, Massachusetts, USA) of HCA to measure the cell area, total neurite length, and maximum neurite length of all identified cell in a plate. Fluorescence images were produced using a multiple bandpass mission filter and matched excitation filters for nuclei and cell bodies, and then acquired using a high-resolution charge-coupled device camera. The system uses an automated inverted epifluorescence microscope to focus and record images from multiple fields in each individual well.
Data are presented as mean±SEM. Statistical analysis of the data was carried out by one-way analysis of variance, followed by Fisher’s least significant difference test our in test. all analyses were carried out using SPSS 20.0 (IBM, Armonk, New York, USA). A P value less than 0.05 was considered a statistically significant difference.
Leonurine reversed CORT-induced cell death in PC12 cells
PC12 cells are used commonly for the establishment of depression models in vitro when they are combined with the administration of CORT 19. To obtain an appropriate depression model, PC12 cells were treated with different concentrations of CORT. When treated with 400 μM CORT for 24 h, cell viability decreased to ~50% (Fig. 1a); thus, this concentration was used in subsequent experiments in vitro.
The MTT assay was performed to investigate the damage to PC12 cells at different concentrations of CORT and the effects of leonurine on CORT-induced cell death. When PC12 cells were exposed to CORT at 400 μM for 24 h, cell viabilities of the different groups (Normal, PBS, LEO 10, 20, 40, 60, 80, and 100 μM) were 100, 49.1, 52.3, 56.8, 64.4, 75.4, 63.2, and 60.7%, respectively. The cell viability of the PBS group was significantly lower than the others, whereas leonurine increased cell viability in a concentration-dependent manner. The prosurvival effect of leonurine was observed at 60 μM (Fig. 1b).
Leonurine promoted CORT-induced cell neurite outgrowth in PC12 cells
Neurite outgrowth is a critical cellular process underlying nervous system development that can be quantified by HCA using automated microscopy and image analysis 20. Images were captured automatically using the Array Scan HCA platform (PerkinElmer, Boston, Massachusetts, USA) and analyzed using the Harmony system, which contains morphological endpoints including cell area, total neurite length, and maximum neurite length.
The outgrowth of axonal and dendritic processes (neurites) is a hallmark of neuronal differentiation and maturation 21. CORT induced a significant decrease in total neurite length [F(2,9)=110.1, P=0.001], maximum neurite length [F(2,9)=180.2, P=0.001], and cell area [F(2,9)=164.3, P=0.001] compared with the normal group. The effects of leonurine on neurite outgrowth in vitro are shown in Fig. 2. Leonurine promoted total neurite outgrowth [F(3,12)=87.7, P=0.007] and maximum neurite length [F(3,12)=146.6, P=0.001], and also increased cell area [F(3,12)=151.4, P=0.002] compared with the PBS group. This action was strengthened after treatment with the SGK1 inhibitor GSK650394, LEO+GSK650394 promoted total neurite outgrowth [F(4,15)=76.6, P=0.007] and maximum neurite length [F(4,15)=132.7, P=0.004], and also induced an increase >in the cell area [F(4,15)=257.5, P=0.001] compared with the PBS group. However, the effect of LEO+GSK650394 on total neurite outgrowth [F(4,15)=76.6, P=0.34], maximum neurite length [F(4,15)=132.7, P=0.69], and cell area [F(4,15)=257.5, P=0.16] showed no significant difference compared with the LEO group (Fig. 2).
In contrast, after treatment with GR inhibitor RU486, leonurine exerted the opposite effect on morphological endpoints compared with GSK650394. LEO+RU486 inhibited total neurite outgrowth [F(4,15)=106.7, P=0.002] and maximum neurite length [F(4,15)=107.1, P=0.001], and also decreased cell area [F(4,15)=289.2, P=0.001] compared with the PBS group. However, the effect of LEO+RU486 on total neurite outgrowth [F(4,15)=106.7, P=0.15], maximum neurite length [F(4,15)=107.1, P=0.48], and cell area [F(4,15)=289.2, P=0.32] showed no significant difference compared with the LEO group (Fig. 2).
The protective effect of leonurine was influenced by inhibiting GR and SGK1
First, we evaluated whether GR and SGK1 were involved in the effect of leonurine on PC12 cells after different drug treatments. We pretreated the cells with inhibitors of GR (RU486, 10 μM) and SGK1 (GSK650394, 20 μM), and then exposed them to CORT (400 μM) in the presence or absence of leonurine (60 μM) for 40 min. Cell viability was determined using an MTT assay. PBS+CORT induced a significant decrease in cell viability (49.1% compared with the normal group), whereas leonurine increased cell viability (73.4% compared with the normal group). Notably, the protective effect of leonurine against CORT-induced cell death was attenuated by RU486 (52.2% compared with the normal group), but this effect was strengthened by GSK650394 (76.5% compared with the normal group), suggesting the involvement of both GR and SGK1 in the effect of leonurine (Fig. 3a). The cell viability was decreased in the PBS [F(2,9)=408.7, P=0.002] group, whereas LEO [F(3,12)=355.4, P=0.004] and LEO+GSK650394 [F(3,12)=355.4, P=0.005] induced a significant increase in cell viability compared with the PBS group.
We then examined whether leonurine could protect PC12 cells by regulating neurotrophic proteins and nerve apoptosis through the GR/SGK1 signaling pathway. In our study, the expression of GR [F(2,9)=206.1, P=0.002], BDNF [F(2,9)=77.8, P=0.003], NT-3 [F(2,9)=110.3, P=0.001], and BCL-2 [F(2,9)=353.1, P=0.001] in CORT-cultured PC12 cells was low in the PBS group, whereas the expression of SGK1 [F(2,9)=181.1, P=0.001] increased. After treatment with leonurine, the expression of GR [F(2,9)=206.1, P=0.001], BDNF [F(2,9)=77.8, P=0.001], NT-3 [F(2,9)=110.3, P=0.001], and BCL-2 [F(2,9)=353.1, P=0.002] increased and that of SGK1 [F(2,9)=181.1, P=0.004] decreased (Figs 3 and 4).
However, after treatment with RU486, LEO induced a significant decrease in the expression of GR [F(4,15)=88.3, P=0.003], BDNF [F(4,15)=134.7, P=0.001], NT-3 [F(4,15)=146.8, P=0.002], and BCL-2 [F(4,15)=297.5, P=0.005] and induced an increase in the expression of SGK1 [F(4,15)=157.9, P=0.006], but there were no differences between LEO treatment with RU486 or not for all five indexes (P>0.05).
Compared with treatment with RU486, GSK650394 had the opposite effect (Figs 3 and 4). LEO+GSK650394 promoted the expression of GR [F(4,15)=194.3, P=0.003], BDNF [F(4,15)=79.6, P=0.004], NT-3 [F(4,15)=138.5, P=0.002], and BCL-2 [F(4,15)=280.9, P=0.001], and decreased the expression of SGK1 [F(4,15)=148.7, P=0.003] compared with the PBS group. However, the effect of LEO+GSK650394 on GR [F(4,15)=194.3, P=0.007], BDNF [F(4,15)=79.6, P=0.007], NT-3 [F(4,15)=138.5, P=0.007], BCL-2 [F(4,15)=280.9, P=0.007], and SGK1 [F(4,15)=148.7, P=0.007] showed no significant difference compared with the LEO group (Fig. 2).
The present results show that CORT caused neurotoxicity in PC12 cells, whereas leonurine prevented cell death mediated by GR/SGK1 signaling. This conclusion was supported by the following observations: (i) treatment with CORT in PC12 cells caused cell death, whereas leonurine significantly reversed the toxic effect of CORT; (ii) inhibition of GR blocked the neuroprotective effect of leonurine on CORT-induced PC12 cell death, whereas inhibition of SGK1 promoted the effect of leonurine; (iii) leonurine exerted a significant protective effect on PC12 cells, increasing the levels of BDNF, NT-3, and BCL-2, while decreasing the expression of SGK1. All of these effects of leonurine were essentially identical to those observed with fluoxetine. The present study confirmed that CORT causes neurotoxicity in PC12 cells accompanied by damaged cell morphology, reduced neurite outgrowth, and disruption of the GR/SGK1 signaling pathway.
CORT is associated closely with the occurrence of depression 22. Administration of CORT has been used to establish models of major depression in vitro and in vivo23,24. The PC12 cell line is widely used as a model system to study a variety of neuronal functions, and given the high level of GRs expressed in PC12 cells, they are very sensitive to glucocorticoid exposure 25,26. It has been reported that CORT can induce apoptosis and damage in PC12 cells and produce depression-like behavior in animal models 27,28. Drugs that can reverse CORT-induced neurotoxicity may thus have therapeutic potential for preventing or treating depression.
Considerable data suggest that excessive and prolonged chronic stress results in hyperactivity of the HPA axis, which may be involved in the pathogenesis of depression 29,30. Cortisol exerts direct toxic effects on the brain, such as reduced neurotropic factors and neuroplasticity, and also promotes apoptosis 31. Indeed, the average concentration of cortisol is reportedly higher in depressed patients than in healthy controls 32. On the basis of the critical role of GR in the HPA axis and in mediating the effects of glucocorticoids on the brain, it is noteworthy that GR is a potential target for antidepressant drugs 33. SGK1 is a mediator of the effects of glucocorticoids on GR function and neurogenesis, and it also acts as a key intermediary between stress and depression 34. Accumulating studies have shown that SGK1 may be a downstream regulator of glucocorticoids and may play a role in the partial effects of glucocorticoids on brain function 35,36.
Hippocampal injury is closely related to depression, which is manifested by hippocampal nerve regeneration disorder and neurotrophic and synaptic plasticity deficits. Interestingly, SGK1 has been reported to be correlated negatively with BDNF, which may provide a potential mechanism for the impaired neurogenesis observed in depression 37. BDNF and NT-3 are members of the neurotrophin family that serve as biomarker proteins closely related to depression. A large number of preclinical studies have shown that a variety of stressors can reduce the activity of the BDNF and NT-3 pathway in the hippocampus, and that antidepressants can enhance pathway activity 38,39. Neurotrophic and neural apoptotic activity can thus interact with each other. BDNF can affect neural apoptosis by regulating the expression of BCL-2 40.
Leonurine exerts neuroprotective effects on ischemic stroke, Parkinson’s disease, and Alzheimer’s disease in animal models 41,42, and can rescue behavioral deficits in animals, promote neuronal survival, and modulate inflammation. However, the effect of leonurine on neuropsychiatric disorders, particularly major depression, remains unknown. Therefore, we used CORT-cultured PC12 cells exposed to GR and an SGK1 inhibitor to study the antidepressant mechanisms of leonurine. Our results showed that leonurine impacted the expression of GR, BDNF, NT-3, BCL-2, and SGK1, whereas RU486 and GSK650394 inhibited and promoted this activity, respectively. Taken together, our results suggest that leonurine exerts antidepressant effects that may control the GR/SGK1 signaling pathway to regulate neurite outgrowth and neurotrophic activity in CORT-cultured PC12 cells.
The present study indicated that leonurine showed antidepressant-like properties in a CORT-induced depression model in PC12 cells, which produced beneficial effects on neurite outgrowth and neurotrophic factors. The action of leonurine was possibly mediated by its ability to increase GR, BDNF, NT-3, and BCL-2 levels while decreasing the expression of SGK1. The underlying mechanism may involve the GR/SGK1 signaling pathway.
This study was financially supported by grants from the National Natural Science Foundation of Hunan (2018JJ3388, 2017JJ3235), National Natural Science Foundation of China (81403387) and the Provincial Department of education innovation platform open fund project of Hunan (16K067,17B201). Also, it was supported by the domestic first class construction discipline of Chinese Medicine in Hunan University of Chinese Medicine.
Authors’ contributions: Conceived and designed the experiments: Pan Meng, Xiaodan Liu, and Jingying Fan. Performed experiments: Pan Meng, Qing Zhu, Dan Liu, and Hui Yang. Analysis and interpretation of data: Pan Meng, Xiaoyuan Lin, and Wei Su. Writing and review of the manuscript: Pan Meng, Hui Yang, Xiaoyuan Lin, and Wei Su. Study supervision: Yuhong Wang, Pan Meng, and Qing Zhu.
Conflicts of interest
There are no conflicts of interest.
1. Kim HD, Hesterman J, Call T, Magazu S, Keeley E, Armenta K, et al. SIRT1 mediates depression-like behaviors in the nucleus accumbens. J Neurosci 2016; 36:8441–8452.
2. Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med 2013; 43:471–481.
3. Niizuma K, Endo H, Chan PH. Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival. J Neurochem 2009; 109 (Suppl 1):133–138.
4. Furtado M, Katzman MA. Examining the role of neuroinflammation in major depression. Psychiatry Res 2015; 229: 27–36.
5. Heller AS, Ezie CEC, Otto AR, Timpano KR. Model-based learning and individual differences in depression: the moderating role of stress. Behav Res Ther 2018; 111:19–26.
6. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008; 31:464–468.
7. Zhang K, Pan X, Wang F, Ma J, Su G, Dong Y, et al. Baicalin promotes hippocampal neurogenesis via SGK1- and FKBP5-mediated glucocorticoid receptor phosphorylation in a neuroendocrine mouse model of anxiety/depression. Sci Rep 2016; 6:30951.
8. Polleux F, Snider W. Initiating and growing an axon. Cold Spring Harb Perspect Biol 2010; 2:a001925.
9. Terada K, Kojima Y, Watanabe T, Izumo N, Chiba K, Karube Y. Inhibition of nerve growth factor-induced neurite outgrowth
from PC12 cells by dexamethasone: signaling pathways through the glucocorticoid receptor and phosphorylated Akt and ERK1/2. PLoS One 2014; 9:e93223.
10. Miyata S, Koyama Y, Takemoto K, Yoshikawa K, Ishikawa T, Taniguchi M, et al. Plasma corticosterone
activates SGK1 and induces morphological changes in oligodendrocytes in corpus callosum. PLoS One 2011; 6:e19859.
11. Wu X, Wu J, Xia S, Li B, Dong J. Icaritin opposes the development of social aversion after defeat stress via increases of GR mRNA and BDNF mRNA in mice. Behav Brain Res 2013; 256:602–608.
12. Hoschl C, Hajek T. Hippocampal damage mediated by corticosteroids--a neuropsychiatric research challenge. Eur Arch Psychiatry Clin Neurosci 2001; 251 (Suppl 2):II81–II88.
13. Murakami S, Imbe H, Morikawa Y, Kubo C, Senba E. Chronic stress, as well as acute stress, reduces BDNF mRNA expression in the rat hippocampus but less robustly. Neurosci Res 2005; 53:129–139.
14. Lu Y, Ho CS, McIntyre RS, Wang W, Ho RC. Effects of vortioxetine and fluoxetine on the level of Brain Derived Neurotrophic Factors (BDNF) in the hippocampus of chronic unpredictable mild stress-induced depressive rats. Brain Res Bull 2018; 142:1–7.
15. Liu XH, Pan LL, Chen PF, Zhu YZ. Leonurine
improves ischemia-induced myocardial injury through antioxidative activity. Phytomedicine 2010; 17:753–759.
16. Zhang Y, Guo W, Wen Y, Xiong Q, Liu H, Wu J, et al. SCM-198 attenuates early atherosclerotic lesions in hypercholesterolemic rabbits via modulation of the inflammatory and oxidative stress pathways. Atherosclerosis 2012; 224:43–50.
17. Jia M, Li C, Zheng Y, Ding X, Chen M, Ding J, et al. Leonurine
exerts antidepressant-like effects in the chronic mild stress-induced depression model in mice by inhibiting neuroinflammation. Int J Neuropsychopharmacol 2017; 20:886–895.
18. He X, Zhu Y, Wang M, Jing G, Zhu R, Wang S. Antidepressant effects of curcumin and HU-211 coencapsulated solid lipid nanoparticles against corticosterone
-induced cellular and animal models of major depression. Int J Nanomedicine 2016; 11:4975–4990.
19. Tian JS, Liu SB, He XY, Xiang H, Chen JL, Gao Y, et al. Metabolomics studies on corticosterone
-induced PC12 cells: a strategy for evaluating an in vitro depression model and revealing the metabolic regulation mechanism. Neurotoxicol Teratol 2018; 69:27–38.
20. Radio NM. Neurite outgrowth
assessment using high content analysis methodology. Methods Mol Biol 2012; 846:247–260.
21. Radio NM, Freudenrich TM, Robinette BL, Crofton KM, Mundy WR. Comparison of PC12 and cerebellar granule cell cultures for evaluating neurite outgrowth
using high content analysis. Neurotoxicol Teratol 2010; 32:25–35.
22. Anacker C, Zunszain PA, Carvalho LA, Pariante CM. The glucocorticoid receptor: pivot of depression and of antidepressant treatment? Psychoneuroendocrinology 2011; 36:415–425.
23. Liu Y, Shen S, Li Z, Jiang Y, Si J, Chang Q, et al. Cajaninstilbene acid protects corticosterone
-induced injury in PC12 cells by inhibiting oxidative and endoplasmic reticulum stress-mediated apoptosis. Neurochem Int 2014; 78:43–52.
24. Zhang HY, Zhao YN, Wang ZL, Huang YF. Chronic corticosterone
exposure reduces hippocampal glycogen level and induces depression-like behavior in mice. J Zhejiang Univ Sci B 2015; 16:62–69.
25. Polman JA, Welten JE, Bosch DS, de Jonge RT, Balog J, van der Maarel SM, et al. A genome-wide signature of glucocorticoid receptor binding in neuronal PC12 cells. BMC Neurosci 2012; 13:118.
26. Wang H, Zhou X, Huang J, Mu N, Guo Z, Wen Q, et al. The role of Akt/FoxO3a in the protective effect of venlafaxine against corticosterone
-induced cell death in PC12 cells. Psychopharmacology (Berl) 2013; 228:129–141.
27. Chen L, Wang X, Lin ZX, Dai JG, Huang YF, Zhao YN. Preventive effects of ginseng total saponins on chronic corticosterone
-induced impairment in astrocyte structural plasticity and hippocampal atrophy. Phytother Res 2017; 31:1341–1348.
28. Zhang H, Zhao Y, Wang Z. Chronic corticosterone
exposure reduces hippocampal astrocyte structural plasticity and induces hippocampal atrophy in mice. Neurosci Lett 2015; 592:76–81.
29. Snyder JS, Soumier A, Brewer M, Pickel J, Cameron HA. Adult hippocampal neurogenesis buffers stress responses and depressive behaviour. Nature 2011; 476:458–461.
30. Gelman PL, Flores-Ramos M, Lopez-Martinez M, Fuentes CC, Grajeda JP. Hypothalamic-pituitary-adrenal axis function during perinatal depression. Neurosci Bull 2015; 31:338–350.
31. Zhao L, Ren H, Gu S, Li X, Jiang C, Li J, et al. rTMS ameliorated depressive-like behaviors by restoring HPA axis balance and prohibiting hippocampal neuron apoptosis in a rat model of depression. Psychiatry Res 2018; 269:126–133.
32. Gorwood P, Corruble E, Falissard B, Goodwin GM. Toxic effects of depression on brain function: impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients. Am J Psychiatry 2008; 165:731–739.
33. Lu J, Fu L, Qin G, Shi P, Fu W. The regulatory effect of Xiaoyao San on glucocorticoid receptors under the condition of chronic stress. Cell Mol Biol (Noisy-le-grand) 2018; 64:103–109.
34. Anacker C, Cattaneo A, Musaelyan K, Zunszain PA, Horowitz M, Molteni R, et al. Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis. Proc Natl Acad Sci USA 2013; 110:8708–8713.
35. Li YC, Wang LL, Pei YY, Shen JD, Li HB, Wang BY, et al. Baicalin decreases SGK1 expression in the hippocampus and reverses depressive-like behaviors induced by corticosterone
. Neuroscience 2015; 311:130–137.
36. Luca F, Kashyap S, Southard C, Zou M, Witonsky D, Di Rienzo A, et al. Adaptive variation regulates the expression of the human SGK1 gene in response to stress. PLoS Genet 2009; 5:e1000489.
37. Lang F, Strutz-Seebohm N, Seebohm G, Lang UE. Significance of SGK1 in the regulation of neuronal function. J Physiol 2010; 588 (Pt 18): 3349–3354.
38. Shen J, Xu L, Qu C, Sun H, Zhang J. Resveratrol prevents cognitive deficits induced by chronic unpredictable mild stress: Sirt1/miR-134 signalling pathway regulates CREB/BDNF expression in hippocampus in vivo and in vitro. Behav Brain Res 2018; 349:1–7.
39. Oglodek EA, Just MJ, Szromek AR, Araszkiewicz A. Melatonin and neurotrophins NT-3, BDNF, NGF in patients with varying levels of depression severity. Pharmacol Rep 2016; 68:945–951.
40. Wang X, Xie Y, Zhang T, Bo S, Bai X, Liu H, et al. Resveratrol reverses chronic restraint stress-induced depression-like behaviour: involvement of BDNF level, ERK phosphorylation and expression of Bcl-2 and Bax in rats. Brain Res Bull 2016; 125:134–143.
41. Shi XR, Hong ZY, Liu HR, Zhang YC, Zhu YZ. Neuroprotective effects of SCM198 on 6-hydroxydopamine-induced behavioral deficit in rats and cytotoxicity in neuronal SH-SY5Y cells. Neurochem Int 2011; 58:851–860.
42. Hong ZY, Yu SS, Wang ZJ, Zhu YZ. SCM-198 ameliorates cognitive deficits, promotes neuronal survival and enhances CREB/BDNF/TrkB signaling without affecting Aβ burden in AβPP/PS1 mice. Int J Mol Sci 2015; 16:18544–18563.